Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novavax

Check Out What Whales Are Doing With NVAX

Someone with a lot of money to spend has taken a bullish stance on Novavax (NASDAQ:NVAX). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Novavax Crashes As Alternative To Pfizer, Moderna Covid Shots Lags Estimates

Novavax reported lighter-than-expected first-quarter sales and profit after launching its Covid vaccine in November. NVAX stock fell.

Investors Business Daily

Why Novavax Shares Are Falling After Hours

Novavax Inc (NASDAQ: NVAX) shares are trading lower in Monday's after-hours session after the company reported worse-than-expected financial results.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

How Novavax Stock Looks Headed Into Q1 Earnings

Novavax, Inc. (NASDAQ: NVAX) is set to print its first-quarter financial results after the market close on Thursday. The stock was trading more than 6% lower, at one point, heading into the event.

Benzinga

Earnings Preview: Novavax

Novavax (NASDAQ:NVAX) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that Novavax will report an earnings per share (EPS) of $2.69.

Benzinga

Novavax Seeks Approval For COVID-19 Shot Among Adolescents In Britain

Novavax Inc (NASDAQ:NVAX) filed an application with Britain's drugs regulator for the authorization of its COVID-19 vaccine among adolescents aged 12 and older. Britain had in February cleared the two-dose vaccine, Nuvaxovid, for use in adults. Novavax's submission includes data from a late-stage trial in the U.S., where the vaccine showed 80% efficacy among…

Benzinga

Novavax Whale Trades For May 03

A whale with a lot of money to spend has taken a noticeably bearish stance on Novavax. Looking at options history for Novavax (NASDAQ:NVAX) we detected 45 strange trades.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Novavax Surges As Its Covid Shot Approaches The FDA Finish Line

The Food and Drug Administration said Friday its panel of experts will discuss Novavax's Covid vaccine in June, leading NVAX stock to surge.

Investors Business Daily

Here's How Much $100 Invested In Novavax 5 Years Ago Would Be Worth Today

Novavax (NASDAQ:NVAX) has outperformed the market over the past 5 years by 13.46% on an annualized basis producing an average annual return of 25.46%. Currently, Novavax has a market capitalization of $3.83 billion.

Benzinga

This Is What Whales Are Betting On Novavax

A whale with a lot of money to spend has taken a noticeably bullish stance on Novavax. Looking at options history for Novavax (NASDAQ:NVAX) we detected 17 strange trades.

Benzinga

Why Novavax Shares Are Rising

Shares of vaccine companies, including Novavax, Inc. (NASDAQ: NVAX), are trading higher amid COVID-19 concerns due to rising cases in China.

Benzinga

Moderna vs. Novavax: Which Stock is a Better Investment?

The biotech industry is playing a crucial role in fighting against COVID-19 and is also making significant progress in developing cures for several other diseases with the help of advanced technologies. So, biotech companies Moderna (MRNA) and Novavax (NVAX) are well-positioned to continue benefiting from the industry’s solid growth prospects.…

StockNews.com

Novavax's COVID-19/Influenza Combo Vaccine Shows Immunogenicity In Early-Study

Novavax Inc (NASDAQ:NVAX) has announced initial results from the Phase 1/2 trial of its COVID-Influenza Combination Vaccine (CIC), combining the COVID-19 vaccine, NVX-CoV2373, and its quadrivalent influenza vaccine candidate. The CIC trial demonstrated that the combination vaccine is feasible, well-tolerated, and immunogenic. The safety and tolerability profile of the combination vaccine was consistent…

Benzinga

If You Invested $100 In Novavax 5 Years Ago, Here's How Much You Would Have Today

Novavax (NASDAQ:NVAX) has outperformed the market over the past 5 years by 13.94% on an annualized basis producing an average annual return of 27.26%. Currently, Novavax has a market capitalization of $4.14 billion.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

What's Going On With Novavax Stock Today?

Novavax Inc (NASDAQ: NVAX) shares are trading lower Tuesday. The stock fell to new 52-week lows early in the session, but has since recovered.

The Independent UK

Japan approves Novavax COVID-19 vaccine

Japan’s health ministry formally approved Novavax’s COVID-19 vaccine, a fourth foreign-developed tool to combat the infections

Benzinga

Japan's Health Ministry Panel OKs Approval Of Novavax's COVID-19 Vaccine: Report

Japan's health ministry panel authorized a plan to approve Novavax Inc's (NASDAQ:NVAX) COVID-19 vaccine, which is set to be the fourth such vaccine to be approved in Japan. It will be available for first and second shots with an interval of three weeks. The Novavax product is a recombinant protein vaccine that uses…

Investors Business Daily

Novavax And Its Plan To Target The Vaccine Resistant Notch Another Win

Swiss officials authorized Novavax's Covid vaccine on Wednesday, and NVAX stock popped, though it remains below its key lines.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Novavax's COVID-19 Vaccine Approved In Switzerland

Swissmedic, the Swiss Agency for Therapeutic Products, has granted conditional marketing authorization for Novavax Inc's (NASDAQ:NVAX) Nuvaxovid COVID-19 Vaccine for individuals 18 years of age and older. The vaccine, also known as NVX-CoV2373, is the first protein-based vaccine authorized for use in Switzerland. The Swissmedic decision was based on two pivotal Phase 3 clinical…

Benzinga

What's Going On With Novavax Shares Today?

Novavax Inc (NASDAQ: NVAX) shares are trading significantly lower Tuesday. According to data from Benzinga Pro, Tuesday's trading volume is in line with Novavax's average trading volume over a 100-day period.

The Independent UK

Novavax asks EU regulator to clear COVID vaccine for teens

The pharmaceutical developer Novavax says it has asked the European Medicines Agency to extend the authorization of its coronavirus vaccine to children aged 12 to 17 amid a surge of disease across the continent

Benzinga

If You Invested $1000 In Novavax 5 Years Ago, Here's How Much You Would Have Today

Novavax (NASDAQ:NVAX) has outperformed the market over the past 5 years by 12.42% on an annualized basis producing an average annual return of 26.64%. Currently, Novavax has a market capitalization of $5.77 billion.

Benzinga

EMA Starts Review Of Sanofi-GlaxoSmithKline's COVID-19 Vaccine

The European Medicines Agency has started reviewing Sanofi SA (NASDAQ:SNY) and its partner GlaxoSmithKline Plc's (NYSE:GSK) application seeking conditional authorization for their COVID-19 vaccine. The vaccine candidate, Vidprevtyn, was already being evaluated under a rolling review by EMA. The drugmakers had earlier said that they would seek regulatory approval for their COVID-19 vaccine to be…

Benzinga

Looking At Novavax's Recent Whale Trades

Salon

Rich versus poor with new COVID vaccine

"There are still a lot of unvaccinated people in poor countries and, once again, they are at the back of the line," said one expert.

1 … 6 7 8 9

People

Shigeyuki Goto

10 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

World Health Organization

903 stories

WSJ

401 stories

Food and Drug Administration

European Medicines Agency

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.